AI assistant
AbbVie Inc. — Director's Dealing 2021
Jul 2, 2021
29755_dirs_2021-07-02_d455caf0-f4c9-4391-8c11-a2551b5e5aab.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AbbVie Inc. (ABBV)
CIK: 0001551152
Period of Report: 2021-06-30
Reporting Person: LIDDY EDWARD M (Director)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-06-30 | Stock Equivalent Units | $112.67 | A | 284 | Acquired | Common Stock (284) | Direct |
Footnotes
F1: Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The cash equivalent of 1,748 stock equivalent units in the Abbott account was paid to the director upon his retirement from Abbott's board on May 1, 2021. The stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.
F2: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.